3×5 Partners
3×5 Partners is a venture capital firm based in Portland, Oregon, founded in 2011. The firm specializes in investments within the life sciences and resource-driven sectors, focusing on companies that contribute to the sustainable consumption of resources such as energy, food, waste, and water. It aims to improve patient outcomes through innovations in biopharma and medical devices. 3×5 Partners seeks to identify solution leaders in these fields, believing they will emerge as significant and valuable companies in the future. The firm has managed over 20 companies and has deployed approximately $390 million across its funds and special purpose vehicles. Its investment strategy includes targeting discovery tools in healthcare, biotechnology, energy, and climate tech, with a preference for minority stake investments in companies with transaction values ranging from $15 million to $20 million.
Kaleidoscope Group PBC is a Minneapolis-based company that specializes in providing a cloud-based software platform for designing, building, and managing scholarship programs. The platform connects scholarship funders with students, facilitating a streamlined marketplace that matches qualified candidates with tailored scholarship opportunities. By offering a comprehensive scholarship management solution, Kaleidoscope allows various organizations and individuals, including fund leaders, artists, entrepreneurs, and professionals, to effectively administer and host their scholarship initiatives. Founded in 2016 by Gregory Dehn, Kaleidoscope Group aims to create a frictionless experience in scholarship management.
Koya Medical, Inc. develops technology device to treat cancer related chronic lymphedema and venous diseases. The company was founded in 2018 and is based in Oakland, California.
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.
Claros Technologies is an advanced materials company that develops safe and sustainable products with zero toxic waste. It strives to lead the industry towards a holistic approach to materials design and innovation. It was founded in 2018 and is based in St Paul, Minnesota.
Fervo Energy is a next-generation geothermal developer generating clean power in new places. Fervo Energy commercializes proprietary technology to own, develop, and operate geothermal assets as the dispatchable foundation to a 100% clean energy future.
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.
Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip.
It was founded in 2008 and headquartered in St Louis, Missouri.
Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions.
Smart Wires was founded in 2010 and headquartered in San Francisco, California.
InterVene, Inc. is a medical device company based in South San Francisco, California, focused on developing innovative catheter-based therapies for chronic venous insufficiency (CVI) caused by deep vein valve failure. Founded in 2011, InterVene aims to transform the treatment of severe venous disease in the legs by introducing a novel, non-implantable catheter approach that enables physicians to create new vein valves. This technology addresses a significant unmet need for patients suffering from painful venous stasis ulcers and other debilitating symptoms associated with deep vein reflux. By providing an effective therapy for CVI, InterVene seeks to improve the quality of life for millions of Americans affected by this condition.
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.
Fishpeople Seafood is a food production company that specializes in providing grocery retail, and sustainable seafood. The company is a dynamic organization experiencing rapid growth and is disrupting the seafood industry status quo by introducing innovative and sustainable seafood products. Fishpeople Seafood was founded in 2012 and is headquartered in Portland, Oregon.